Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
- PMID: 33259154
- PMCID: PMC7722690
- DOI: 10.1056/NEJMc2031670
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
Figures

Comment in
-
Impact of COVID-19 on Clinical Care and Research in Cancer Imaging: Where We Are Now.Radiol Imaging Cancer. 2021 Jan 22;3(1):e210003. doi: 10.1148/rycan.2021210003. eCollection 2021 Jan. Radiol Imaging Cancer. 2021. PMID: 33778764 Free PMC article. No abstract available.
References
-
- Centers for Disease Control and Prevention. Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in healthcare settings (interim guidance). August 10, 2020. (https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-p...).
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous